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Treatment of irritable bowel syndrome
Strategies involve single receptor blockade and non-pharmacological interventions
Irritable bowel syndrome is characterised bydiverse symptoms including abdominal pain,altered bowel function (increased bowel frequency,
constipation), bloating, abdominal distension, the
sensation of incomplete evacuation, and the increased
passage of mucus.w1 No unifying hypothesis explains all
these symptoms, and no single agent will alleviate all
components of the symptom complex. The currently
favoured model to explain the symptoms includes cen-
tral and end organ components. These may be
combined into an integrated hypothesis that incorpo-
rates psychological factors (stress, distress, affective dis-
order) and dysfunction of the gut (disorders of motility,
visceral hypersensitivity).1 Current standard drug treat-
ment generally entails a symptom directed approach
with drugs aimed at pain, constipation, and diarrhoea.2
Development of new drugs has focused mainly on
agents that modify the effects of 5-hydroxytryptamine
(5-HT) in the gut. Alternatives to this single receptor
approach exist, although not all patients respond to
educational and psychological interventions, and treat-
ment with drugs will remain an option for non-
responders.
As a mediator of the motor and secretory
responses to the ingestion of food, 5-HT has an impor-
tant physiological role. Growing evidence shows that
some aspects of the pathophysiology of irritable bowel
syndrome may affect the 5-HT axis.w2 Specific 5-HT3
and 5-HT4 receptors have been identified as therapeu-
tic targets.
Alosetron and cilansetron, which are 5-HT3 recep-
tor antagonists, were devised to reduce pain and retard
transit and therefore be beneficial in irritable bowel
syndrome that manifests predominantly as diarrhoea.
Randomised controlled trials indicate that both have
some efficacy in patients with diarrhoea predominant
irritable bowel syndrome, although alosetron is
effective only in women.3 Although alosetron was
licensed in the United States in 2000, it was
subsequently withdrawn because many patients devel-
oped ischaemic colitis and severe constipation.w3 Many
of these patients required admission to hospital, and
three of them died. Ischaemic colitis has also been
reported with cilansetron and seems likely to be a class
specific adverse effect. Recent evidence shows that
ischaemic colitis may be increased in patients with irri-
table bowel syndrome,4 and that this may be
influencing the effect of alosetron adversely. The Food
and Drug Administration, however, has challenged this
position.5
The second problem relates to whether the statisti-
cally significant therapeutic gain of about 12% over
placebo translates into a clinically important benefit
for patients with irritable bowel syndrome. A group of
experts has advised that a 10-15% therapeutic gain
would be appropriate for a new drug for irritable bowel
syndrome, although this statement seems to lack
evidence.6
Tegaserod, a 5-HT4 receptor partial agonist and a
prokinetic in the gut, is effective in women with consti-
pation predominant irritable bowel syndrome. The
therapeutic gain over placebo varied substantially in
different trials at 5-20%, again raising the question
whether this is a clinically important effect and
whether a similar therapeutic gain might be obtained
with a simple laxative or soluble fibre. A Cochrane
review confirms the drug’s efficacy in improving the
overall symptoms in irritable bowel syndrome, with a
number needed to treat between 14 and 20, but finds
no effect on individual symptoms of pain and discom-
fort.7 Tegaserod is now available in the United States
and some other countries for the treatment of
constipation predominant irritable bowel syndrome in
women. It is still under evaluation by the European
Agency for Evaluation of Medicinal Products. Tegas-
erod has also been linked to ischaemic colitis,8 but this
assertion has been rebutted on the basis that
this merely represents the incidence in the general
population.9
The science linking 5-HT and irritable bowel
syndrome is appealing, and some progress has been
made in translating this knowledge into new treat-
ments, however, we still have no pharmacological
intervention that will resolve all aspects of the
symptom complex of irritable bowel syndrome in men
and women. An agent directed at a single gut receptor
is unlikely to cure irritable bowel syndrome.
What other options might be worth exploring? The
importance of psychosocial factors in the development
of irritable bowel syndrome has been recognised for
decades. Psychological interventions (psychotherapy,
short and long term hypnotherapy, cognitive behav-
iour therapy) and antidepressants (low and conven-
tional doses) are effective. Cognitive behaviour therapy
has an impressive therapeutic gain of 33% over
control.10 Multidisciplinary education and comprehen-
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sive self management programmes in women have
also been shown to work.11 12
Thompson, however, said recently that most
patients with irritable bowel syndrome require no drug
treatment.w4 For most patients, irritable bowel syn-
drome is an intrusive and sometimes debilitating con-
dition, but it is never fatal in itself. Therefore, we must
be certain that any new treatment is truly effective and
has a clinically significant benefit over placebo, and
must do no harm.
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Primary care for children in the 21st century
General practitioners must adapt to the changed spectrum of illnesses
The British model of general practice is rightlyadmired.1 2 Explicit responsibility for a definedpopulation facilitates a public health dimen-
sion to health care. The training emphasises teamwork,
consultation skills, management of undifferentiated
symptoms, and the integration of psychosocial and
biological aspects of health and illness in the context of
the family and community. These skills are crucial for
working with children and young people and the
recently published national service framework for chil-
dren has a whole section on primary care.3 w1
Therefore, to question the future of children’s health
care in general practice may seem perverse, but there
are several causes for concern.
Although serious acute childhood illness has
become less common, both professionals and parents
worry about overlooking potentially life threatening
conditions. When a child is ill outside surgery hours,
parents accept that they are unlikely to see their usual
doctor and the new contract permits general
practitioners to opt out of 24 hour responsibilities.w2 w3
Out of hours services, such as NHS Direct, often direct
parents to a primary care assessment facility or a hos-
pital emergency department. Even if primary care
organisations can sustain 24 hour cover, more parents
may well decide to bypass primary care and seek emer-
gency care in hospitals, accelerating the move towards
centralised emergency services and more short stay
admissions.w4 w5
Rare complex paediatric conditions need special-
ised management, but chronic neurological, psycho-
social, and mental health problems (in particular
conduct and behavioural disorders) make up a large
part of modern paediatrics,4 yet their care remains
fragmented and the resources allocated inadequate.5
General practitioners have yet to take on a major role
in managing chronic disorders, many of which persist
into adult life,6 although children’s trusts could in the
future facilitate cooperation between health services
and the education and social services provided by local
government.
The 1990 contract encouraged general practition-
ers to provide child health surveillance programmes.
They are well placed to understand how individual
social circumstances might influence each child’s
health and development.w6 The growing evidence for
child health screening and promotion in preschool
facilities and schools underlies government support
for a child health promotion programme.3 w7 w8
Although some doctors enjoy preventive care and
caring for well children, many believe that this is best
delivered by other professional staff such as health visi-
tors. The latter, however, work increasingly on a
geographical basis separate from general practices.
Physical examination, once the preserve of doctors, can
be undertaken by appropriately trained nurses and
midwives, at least where the newborn is concerned and
non-medical staff are increasingly functioning as
independent practitioners.w9 Health promotion for
teenagers is also problematic; they often prefer clinics
near their school or college for sensitive issues like
sexual health because of concerns about the privacy
and confidentiality offered by their local general prac-
tice, despite many practices having sought to reassure
young people by establishing special teenage clinics.7
In other European Union countries and the United
States,8 9 office based paediatricians provide most care,
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